A Phase 3 interventional study of BNT162b2 and BNT162b2.B.1.351 in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 17 sites in United States. Open to participants aged 12 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-22.
Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 8th largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 6th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,574 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 10th largest by enrollment, is one of 10 that started in 2021, is one of 14 in phase 3, and was the 11th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, observer-blind study in healthy individuals.
The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2):
The booster study will evaluate the safety, tolerability, and immunogenicity of 2 SARS-CoV-2 RNA vaccine candidates (BNT162b2 and BNT162b2.B.1.351):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
. individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
Additional Exclusion Criteria for the Booster study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30-microgram dose of US manufactured drug substance (Lot 1)
Biological: BNT162b2
30-microgram dose of US manufactured drug substance (Lot 2)
Biological: BNT162b2
30-microgram dose of US manufactured drug substance (Lot 3)
Biological: BNT162b2
30-microgram dose of EU manufactured drug substance (Lot 4)
Biological: BNT162b2
20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)
Biological: BNT162b2
30-microgram dose
Biological: BNT162b2
30-microgram dose
Biological: BNT162b2.B.1.351
Intramuscular injection
Intramuscular injection
Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study
Geometric mean concentration of full-length S-binding IgG level for individual US lots (US lots 1, 2, and 3) was determined and reported in the descriptive section. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratio of Geometric Mean Concentrations (GMCs) of individual US Lots BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3.
Time frame: 1 Month after Dose 2
Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study
Geometric mean concentration of full-length S-binding IgG level for EU lot and pooled US lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm) were determined and reported in the descriptive section. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratios of GMCs of BNT162b2 30 mcg: EU Lot and pooled US Lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm).
Time frame: 1 Month after Dose 2
Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study
Geometric mean titer for SARS-CoV-2 neutralizing titers for 20 mcg dose and 30 mcg dose of US Lot 1 was determined and reported in the descriptive section. GMTs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) mean of the titers and corresponding CIs based on linear regression model. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and were calculated as the ratio of geometric mean titer of the 20-mcg dose (US Lot 1) to the geometric mean titer of the 30 mcg dose (US Lot 1).
Time frame: 1 Month after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 1. Redness, swelling, and pain at injection site after Dose 1 were reported.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 2. Redness, swelling, and pain at injection site after Dose 2 were reported.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Any Dose: Primary Study
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination. Redness, swelling, and pain at injection site after any dose were reported.
Time frame: Within 7 days after any dose
Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Booster Study
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3. Redness, swelling, and pain at injection site after Dose 3 were reported.
Time frame: Within 7 days after Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 1 were reported.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 2 were reported.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Any Dose: Primary Study
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after any dose were reported.
Time frame: Within 7 days after any dose
Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Booster Study
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 3 were reported.
Time frame: Within 7 days after Dose 3
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2: Primary Study
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
Time frame: Day 1 of Dose 1 up to 1 Month after Dose 2 (for a maximum of 2 months)
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 3 to 1 Month After Dose 3: Booster Study
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
Time frame: From Dose 3 to 1 Month after Dose 3 (for a maximum of 35 days)
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: Baseline (prior to Dose 1 of Primary study)
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: 1 Month after Dose 2 of primary study
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: Before Dose 3
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: 1 Week after Dose 3
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: 1 Month after Dose 3
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain at Baseline: Booster Study
GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Time frame: Baseline (prior to Dose 1 of Primary study)
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 2: Booster Study
GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Time frame: 1 Month after Dose 2 of primary study
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: Before Dose 3
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: 1 Week after Dose 3
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
Time frame: 1 Month after Dose 3
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Baseline (prior to Dose 1 of Primary study)
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: 1 Month after Dose 2 of primary study
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: 1 Week after Dose 3
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: 1 Month after Dose 3
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From 1 Month after Dose 2 to 1 Week after Dose 3
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From 1 Month after Dose 2 to 1 Month after Dose 3
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3 to 1 Week after Dose 3
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3 to 1 Month after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From 1 Month after Dose 2 to 1 Week after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From 1 Month after Dose 2 to 1 Month after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3 to 1 Week after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3 to 1 Month after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
Time frame: From 1 Month after Dose 2 to 1 Week after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
Time frame: From 1 Month after Dose 2 to 1 Month after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3 to 1 Week after Dose 3
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Before Dose 3 to 1 Month after Dose 3
Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study
Seroresponse was defined as greater than equal to (\>=) 4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Month after Dose 2
Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Before Dose 3
Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Week after Dose 3
Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Month after Dose 3
Percentage of Participants With Seroresponse to B.1.351 Variant Strain at 1 Month After Dose 2: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
Time frame: 1 Month after Dose 2
Percentage of Participants With Seroresponse to B.1.351 Variant Strain Before Dose 3: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
Time frame: Before Dose 3
Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Week After Dose 3: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
Time frame: 1 Week after Dose 3
Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Month After Dose 3: Booster Study
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
Time frame: 1 Month after Dose 3
Geometric Mean Concentrations (GMCs) of Full-Length S-Binding IgG Levels at Baseline and 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.
Time frame: Baseline (before Dose 1), 1 Month after Dose 2
Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From Baseline (before Dose 1) up to 1 Month after Dose 2
Geometric Mean Titers (GMT) of SARS-CoV-2 Neutralizing Titers at Baseline and 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.
Time frame: Baseline (before Dose 1), 1 Month after Dose 2
Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 at 1 month after Dose 2 to the geometric mean titers of SARS-CoV-2 at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.
Time frame: From Baseline (before Dose 1) up to 1 Month after Dose 2
This study was conducted in two parts: primary study and booster study.
| Milestone | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|---|---|---|---|---|
| Started | 351 | 352 | 347 | 173 | 351 | 0 | 0 |
| Treated | 351 | 352 | 346 | 173 | 351 | 0 | 0 |
| Completed | 347 | 346 | 344 | 171 | 349 | 0 | 0 |
| Not completed | 4 | 6 | 3 | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Inclusion criteria not met | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 31 | 31 |
| Completed | 0 | 0 | 0 | 0 | 0 | 31 | 31 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Geometric mean concentration of full-length S-binding IgG level for individual US lots (US lots 1, 2, and 3) was determined and reported in the descriptive section. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratio of Geometric Mean Concentrations (GMCs) of individual US Lots BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3.
| Unit per milliliter | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 |
|---|---|---|---|
| Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study | 6299.5 ± 5835.4 | 6231.9 ± 5763.7 | 6774.8 ± 6264.9 |
Geometric mean concentration of full-length S-binding IgG level for EU lot and pooled US lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm) were determined and reported in the descriptive section. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratios of GMCs of BNT162b2 30 mcg: EU Lot and pooled US Lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm).
| Unit per milliliter | BNT162b2 30 mcg: EU Lot | Pooled US Lots |
|---|---|---|
| Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study | 6098.6 (5474.7 to 6793.7) | 6428.8 (6149.5 to 6720.7) |
Geometric mean titer for SARS-CoV-2 neutralizing titers for 20 mcg dose and 30 mcg dose of US Lot 1 was determined and reported in the descriptive section. GMTs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) mean of the titers and corresponding CIs based on linear regression model. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and were calculated as the ratio of geometric mean titer of the 20-mcg dose (US Lot 1) to the geometric mean titer of the 30 mcg dose (US Lot 1).
| Titer | BNT162b2 30 mcg: US Lot 1 | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|
| Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study | 906.3 (847.8 to 968.9) | 976.6 (914.1 to 1043.4) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 1. Redness, swelling, and pain at injection site after Dose 1 were reported.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| Redness | 1.1 (0.3 to 2.9) | 2.0 (0.8 to 4.1) | 2.9 (1.4 to 5.3) | 2.0 (1.2 to 3.0) | 2.3 (0.6 to 5.8) | 2.0 (0.8 to 4.1) |
| Swelling | 2.0 (0.8 to 4.1) | 3.7 (2.0 to 6.2) | 3.8 (2.0 to 6.4) | 3.1 (2.2 to 4.4) | 2.9 (0.9 to 6.6) | 3.4 (1.8 to 5.9) |
| Pain at Injection Site | 82.9 (78.6 to 86.7) | 79.3 (74.6 to 83.4) | 84.6 (80.4 to 88.3) | 82.3 (79.8 to 84.5) | 86.1 (80.1 to 90.9) | 78.1 (73.4 to 82.3) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 2. Redness, swelling, and pain at injection site after Dose 2 were reported.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| Redness | 3.7 (2.0 to 6.3) | 4.0 (2.2 to 6.6) | 4.4 (2.5 to 7.1) | 4.0 (2.9 to 5.4) | 2.9 (1.0 to 6.7) | 3.2 (1.6 to 5.6) |
| Swelling | 4.9 (2.9 to 7.7) | 6.0 (3.8 to 9.0) | 4.7 (2.7 to 7.5) | 5.2 (3.9 to 6.7) | 3.5 (1.3 to 7.4) | 3.7 (2.0 to 6.3) |
| Pain at Injection Site | 80.2 (75.7 to 84.3) | 77.7 (73.0 to 82.0) | 83.1 (78.7 to 86.9) | 80.3 (77.8 to 82.7) | 77.3 (70.3 to 83.4) | 79.6 (75.0 to 83.7) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination. Redness, swelling, and pain at injection site after any dose were reported.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| Redness | 4.6 (2.6 to 7.3) | 5.4 (3.3 to 8.3) | 6.6 (4.2 to 9.8) | 5.5 (4.2 to 7.1) | 4.6 (2.0 to 8.9) | 4.6 (2.6 to 7.3) |
| Swelling | 6.0 (3.7 to 9.0) | 8.8 (6.1 to 12.3) | 7.2 (4.7 to 10.5) | 7.3 (5.8 to 9.1) | 4.6 (2.0 to 8.9) | 6.3 (4.0 to 9.3) |
| Pain at Injection Site | 90.9 (87.4 to 93.7) | 85.8 (81.7 to 89.3) | 91.1 (87.6 to 93.8) | 89.2 (87.2 to 91.0) | 91.3 (86.1 to 95.1) | 89.5 (85.8 to 92.5) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3. Redness, swelling, and pain at injection site after Dose 3 were reported.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Redness | 9.7 ± 2.0 | 3.2 ± 0.1 |
| Swelling | 6.5 ± 0.8 | 6.5 ± 0.8 |
| Pain at Injection site | 90.3 ± 74.2 | 93.5 ± 78.6 |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 1 were reported.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| Fever >=38.0 C | 0.3 (0.0 to 1.6) | 0 (0.0 to 1.0) | 2.0 (0.8 to 4.1) | 0.8 (0.3 to 1.5) | 1.2 (0.1 to 4.1) | 0 (0.0 to 1.0) |
| Fever >=38.0 C to 38.4 C | 0.3 (0.0 to 1.6) | 0 (0.0 to 1.0) | 1.2 (0.3 to 2.9) | 0.5 (0.2 to 1.1) | 0.6 (0.0 to 3.2) | 0 (0.0 to 1.0) |
| Fever >38.4 C to 38.9 C | 0 (0.0 to 1.0) | 0 (0.0 to 1.0) | 0.6 (0.1 to 2.1) | 0.2 (0.0 to 0.7) | 0.6 (0.0 to 3.2) | 0 (0.0 to 1.0) |
| Fever >38.9 C to 40.0 C | 0 (0.0 to 1.0) | 0 (0.0 to 1.0) | 0.3 (0.0 to 1.6) | 0.1 (0.0 to 0.5) | 0 (0.0 to 2.1) | 0 (0.0 to 1.0) |
| Fever >40.0 C | 0 (0.0 to 1.0) | 0 (0.0 to 1.0) | 1 (0.0 to 1.1) | 0 (0.0 to 0.4) | 0 (0.0 to 2.1) | 0 (0.0 to 1.0) |
| Fatigue | 53.3 (47.9 to 58.6) | 45.5 (40.2 to 50.8) | 50.7 (45.3 to 56.1) | 49.8 (46.7 to 52.9) | 49.1 (41.5 to 56.8) | 49.0 (43.7 to 54.4) |
| Headache | 36.2 (31.1 to 41.5) | 32.7 (27.8 to 37.8) | 33.3 (28.4 to 38.6) | 34.1 (31.2 to 37.0) | 38.7 (31.4 to 46.4) | 35.6 (30.6 to 40.9) |
| Chills | 8.5 (5.8 to 12.0) | 7.7 (5.1 to 11.0) | 10.1 (7.2 to 13.8) | 8.8 (7.1 to 10.7) | 8.1 (4.5 to 13.2) | 6.8 (4.4 to 10.0) |
| Vomiting | 0.6 (0.1 to 2.0) | 0.6 (0.1 to 2.0) | 1.2 (0.3 to 2.9) | 0.8 (0.3 to 1.5) | 0.6 (0.0 to 3.2) | 0.9 (0.2 to 2.5) |
| Diarrhea | 9.7 (6.8 to 13.3) | 8.0 (5.4 to 11.3) | 7.8 (5.2 to 11.2) | 8.5 (6.9 to 10.3) | 9.2 (5.4 to 14.6) | 10.0 (7.0 to 13.6) |
| New/worsened muscle pain | 14.5 (11.0 to 18.7) | 13.1 (9.7 to 17.0) | 16.5 (12.8 to 20.9) | 14.7 (12.6 to 17.0) | 17.3 (12.0 to 23.8) | 16.2 (12.5 to 20.5) |
| New/worsened joint pain | 6.8 (4.4 to 10.0) | 6.5 (4.2 to 9.6) | 7.0 (4.5 to 10.2) | 6.8 (5.3 to 8.5) | 7.5 (4.1 to 12.5) | 6.6 (4.2 to 9.7) |
| Use of antipyretic/analgesic medication | 16.8 (13.0 to 21.1) | 14.5 (11.0 to 18.6) | 18.8 (14.9 to 23.4) | 16.7 (14.5 to 19.1) | 22.0 (16.0 to 28.9) | 18.2 (14.3 to 22.7) |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 2 were reported.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| Fever >=38.0 C | 7.2 (4.7 to 10.4) | 6.3 (4.0 to 9.4) | 6.7 (4.3 to 9.9) | 6.7 (5.3 to 8.4) | 8.7 (5.0 to 14.0) | 5.7 (3.5 to 8.7) |
| Fever >=38.0 C to 38.4 C | 4.6 (2.6 to 7.3) | 3.4 (1.8 to 5.9) | 3.2 (1.6 to 5.7) | 3.7 (2.7 to 5.1) | 6.4 (3.2 to 11.2) | 4.3 (2.4 to 7.0) |
| Fever >38.4 C to 38.9 C | 2.0 (0.8 to 4.1) | 2.0 (0.8 to 4.1) | 2.3 (1.0 to 4.5) | 2.1 (1.3 to 3.2) | 1.2 (0.1 to 4.1) | 1.4 (0.5 to 3.3) |
| Fever >38.9 C to 40.0 C | 0.6 (0.1 to 2.1) | 0.9 (0.2 to 2.5) | 0.9 (0.2 to 2.5) | 0.8 (0.3 to 1.5) | 1.2 (0.1 to 4.1) | 0 (0.0 to 1.1) |
| Fever >40.0 C | 0 (0.0 to 1.1) | 0 (0.0 to 1.0) | 0.3 (0.0 to 1.6) | 0.1 (0.0 to 0.5) | 0 (0.0 to 2.1) | 0 (0.0 to 2.1) |
| Fatigue | 69.9 (64.8 to 74.7) | 66.6 (61.4 to 71.5) | 71.4 (66.3 to 76.2) | 69.3 (66.4 to 72.1) | 69.8 (62.3 to 76.5) | 66.7 (61.4 to 71.6) |
| Headache | 57.0 (51.6 to 62.3) | 56.6 (51.2 to 61.8) | 56.9 (51.4 to 62.2) | 56.8 (53.7 to 59.8) | 56.4 (48.6 to 63.9) | 50.6 (45.2 to 55.9) |
| Chills | 28.1 (23.4 to 33.1) | 31.1 (26.3 to 36.3) | 33.8 (28.8 to 39.1) | 31.0 (28.2 to 33.9) | 28.5 (21.9 to 35.9) | 23.6 (19.2 to 28.4) |
| Vomiting | 2.3 (1.0 to 4.5) | 1.4 (0.5 to 3.3) | 2.3 (1.0 to 4.5) | 2.0 (1.3 to 3.1) | 1.7 (0.4 to 5.0) | 1.4 (0.5 to 3.3) |
| Diarrhea | 8.3 (5.6 to 11.7) | 9.1 (6.3 to 12.7) | 7.9 (5.3 to 11.2) | 8.4 (6.8 to 10.3) | 9.3 (5.4 to 14.7) | 6.9 (4.5 to 10.1) |
| New/worsened muscle pain | 32.7 (27.8 to 37.9) | 38.6 (33.4 to 43.9) | 35.6 (30.5 to 40.9) | 35.6 (32.7 to 38.6) | 36.0 (28.9 to 43.7) | 35.6 (30.6 to 40.9) |
| New/worsened joint pain | 19.2 (15.2 to 23.7) | 24.6 (20.2 to 29.4) | 19.2 (15.2 to 23.8) | 21.0 (18.6 to 23.6) | 19.2 (13.6 to 25.9) | 19.5 (15.5 to 24.1) |
| Use of antipyretic/analgesic medication | 35.2 (30.2 to 40.5) | 41.1 (35.9 to 46.5) | 40.8 (35.6 to 46.2) | 39.1 (36.1 to 42.1) | 41.9 (34.4 to 49.6) | 37.9 (32.8 to 43.3) |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after any dose were reported.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| Fever >=38.0 C | 7.4 (4.9 to 10.7) | 6.3 (4.0 to 9.3) | 8.4 (5.7 to 11.8) | 7.3 (5.8 to 9.1) | 9.2 (5.4 to 14.6) | 5.7 (3.5 to 8.7) |
| Fever >=38.0 C to 38.4 C | 4.8 (2.8 to 7.6) | 3.4 (1.8 to 5.9) | 4.0 (2.2 to 6.7) | 4.1 (3.0 to 5.5) | 6.4 (3.2 to 11.1) | 4.3 (2.4 to 7.0) |
| Fever >38.4 C to 38.9 C | 2.0 (0.8 to 4.1) | 2.0 (0.8 to 4.1) | 2.9 (1.4 to 5.2) | 2.3 (1.5 to 3.4) | 1.7 (0.4 to 5.0) | 1.4 (0.5 to 3.3) |
| Fever >38.9 C to 40.0 C | 0.6 (0.1 to 2.0) | 0.9 (0.2 to 2.5) | 1.2 (0.3 to 2.9) | 0.9 (0.4 to 1.6) | 1.2 (0.1 to 4.1) | 0 (0.0 to 1.0) |
| Fever >40.0 C | 0 (0.0 to 1.0) | 0 (0.0 to 1.0) | 0.3 (0.0 to 1.6) | 0.1 (0.0 to 0.5) | 0 (0.0 to 2.1) | 0 (0.0 to 1.0) |
| Fatigue | 78.6 (74.0 to 82.8) | 73.6 (68.6 to 78.1) | 81.0 (76.4 to 85.0) | 77.8 (75.1 to 80.3) | 76.9 (69.9 to 82.9) | 75.5 (70.7 to 79.9) |
| Headache | 66.7 (61.5 to 71.6) | 65.1 (59.8 to 70.0) | 64.3 (59.0 to 69.3) | 65.4 (62.4 to 68.3) | 68.8 (61.3 to 75.6) | 63.8 (58.5 to 68.9) |
| Chills | 32.8 (27.9 to 37.9) | 34.1 (29.1 to 39.3) | 37.2 (32.1 to 42.5) | 34.7 (31.8 to 37.7) | 32.4 (25.5 to 39.9) | 26.2 (21.7 to 31.1) |
| Vomiting | 2.8 (1.4 to 5.2) | 2.0 (0.8 to 4.1) | 3.5 (1.8 to 6.0) | 2.8 (1.9 to 3.9) | 2.3 (0.6 to 5.8) | 2.3 (1.0 to 4.4) |
| Diarrhea | 16.2 (12.5 to 20.5) | 14.2 (10.7 to 18.3) | 13.8 (10.4 to 17.9) | 14.8 (12.7 to 17.1) | 15.0 (10.1 to 21.2) | 15.4 (11.8 to 19.6) |
| New/worsened muscle pain | 38.7 (33.6 to 44.1) | 43.5 (38.2 to 48.8) | 43.2 (37.9 to 48.6) | 41.8 (38.8 to 44.9) | 43.9 (36.4 to 51.7) | 40.5 (35.3 to 45.8) |
| New/worsened joint pain | 23.4 (19.0 to 28.1) | 27.3 (22.7 to 32.2) | 23.9 (19.5 to 28.8) | 24.9 (22.3 to 27.6) | 24.3 (18.1 to 31.4) | 22.2 (18.0 to 26.9) |
| Use of antipyretic/analgesic medication | 41.9 (36.7 to 47.2) | 43.8 (38.5 to 49.1) | 46.4 (41.1 to 51.8) | 44.0 (41.0 to 47.1) | 51.4 (43.7 to 59.1) | 43.6 (38.3 to 49.0) |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 3 were reported.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Fever >=38.0 C | 3.2 (0.1 to 16.7) | 6.5 (0.8 to 21.4) |
| Fever >=38.0 C to 38.4 C | 0 (0.0 to 11.2) | 6.5 (0.8 to 21.4) |
| Fever >38.4 C to 38.9 C | 3.2 (0.1 to 16.7) | 0 (0.0 to 11.2) |
| Fever >38.9 C to 40.0 C | 0 (0.0 to 11.2) | 0 (0.0 to 11.2) |
| Fever >40.0 C | 0 (0.0 to 11.2) | 0 (0.0 to 11.2) |
| Fatigue | 67.7 (48.6 to 83.3) | 83.9 (66.3 to 94.5) |
| Headache | 41.9 (24.5 to 60.9) | 58.1 (39.1 to 75.5) |
| Chills | 25.8 (11.9 to 44.6) | 19.4 (7.5 to 37.5) |
| Vomiting | 3.2 (0.1 to 16.7) | 0 (0.0 to 11.2) |
| Diarrhea | 16.1 (5.5 to 33.7) | 6.5 (0.8 to 21.4) |
| New/worsened muscle pain | 41.9 (24.5 to 60.9) | 19.4 (7.5 to 37.5) |
| New/worsened joint pain | 12.9 (3.6 to 29.8) | 12.9 (3.6 to 29.8) |
| Use of antipyretic/analgesic medication | 32.3 (16.7 to 51.4) | 35.5 (19.2 to 54.6) |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
| Percentage of participants | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|---|---|---|---|
| AEs | 5.4 | 6.0 | 5.2 | 5.5 | 10.4 | 6.8 |
| SAEs | 0 | 0 | 0.3 | 0.1 | 0.6 | 0 |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| AEs | 6.5 | 3.2 |
| SAEs | 0 | 0 |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study | 20.5 (20.5 to 20.5) | 20.5 (20.5 to 20.5) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study | 971.4 (750.5 to 1257.4) | 749.0 (575.2 to 975.3) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study | 263.5 (186.9 to 371.3) | 224.2 (176.4 to 285.1) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study | 2159.3 (1568.4 to 2972.8) | 1283.4 (939.4 to 1753.5) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study | 2035.5 (1502.2 to 2758.1) | 943.3 (699.1 to 1272.7) |
GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
No measurements were reported for this outcome.
GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
No measurements were reported for this outcome.
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study | 103.0 (75.4 to 140.8) | 94.0 (67.5 to 130.8) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study | 1614.1 (1172.8 to 2221.6) | 1729.8 (1160.0 to 2579.4) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
| Titer | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study | 1358.4 (968.5 to 1905.1) | 1411.1 (950.1 to 2095.9) |
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study | 3.4 (2.0 to 5.7) | 3.4 (2.3 to 5.1) |
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study | 6529.1 (5212.9 to 8177.6) | 3796.9 (1899.8 to 7588.4) |
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study | 1834.5 (1458.5 to 2307.5) | 1851.6 (1441.9 to 2377.8) |
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study | 10756.9 (8478.9 to 13647.0) | 10412.3 (7733.0 to 14020.0) |
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study | 7983.0 (6266.0 to 10170.6) | 6676.9 (5242.6 to 8503.6) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study | 1.6 (1.3 to 2.0) | 2.7 (1.3 to 5.9) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study | 1.2 (1.0 to 1.5) | 1.8 (0.9 to 3.6) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study | 5.9 (4.9 to 7.0) | 5.6 (4.4 to 7.2) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study | 4.4 (3.7 to 5.2) | 3.6 (2.9 to 4.5) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study | 2.2 (1.6 to 3.0) | 1.7 (1.3 to 2.2) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study | 2.1 (1.6 to 2.7) | 1.2 (0.9 to 1.6) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study | 8.2 (5.3 to 12.7) | 5.7 (4.5 to 7.3) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study | 7.7 (5.6 to 10.7) | 4.2 (3.2 to 5.5) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
No measurements were reported for this outcome.
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
No measurements were reported for this outcome.
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study | 15.7 (11.2 to 22.0) | 18.4 (13.8 to 24.6) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study | 13.2 (9.6 to 18.1) | 15.0 (11.3 to 19.9) |
Seroresponse was defined as greater than equal to (\>=) 4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study | 100 (87.2 to 100.0) | 100 (86.3 to 100.0) |
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study | 92.6 (75.7 to 99.1) | 92.0 (74.0 to 99.0) |
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study | 100.0 (87.2 to 100.0) | 100.0 (86.3 to 100.0) |
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|
| Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study | 100.0 (87.2 to 100.0) | 100.0 (86.3 to 100.0) |
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
No measurements were reported for this outcome.
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
No measurements were reported for this outcome.
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
No measurements were reported for this outcome.
Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.
No measurements were reported for this outcome.
GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.
| Unit per milliliter | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot |
|---|---|---|---|---|---|
| Baseline | 3.1 (2.7 to 3.5) | 2.6 (2.3 to 3.0) | 2.6 (2.2 to 3.0) | 2.8 (2.5 to 3.0) | 2.6 (2.1 to 3.2) |
| 1 Month After Dose 2 | 6269.8 (5717.7 to 6875.2) | 6222.3 (5721.5 to 6766.9) | 6818.9 (6280.9 to 7403.1) | 6428.7 (6116.6 to 6756.8) | 6098.9 (5446.0 to 6830.1) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | Pooled US Lots | BNT162b2 30 mcg: EU Lot |
|---|---|---|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study | 2036.6 (1744.5 to 2377.7) | 2367.1 (2028.6 to 2762.2) | 2645.2 (2271.2 to 3080.8) | 2331.9 (2133.7 to 2548.5) | 2373.8 (1901.2 to 2963.9) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.
| Titer | BNT162b2 30 mcg: US Lot 1 | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|
| Baseline | 20.5 (20.5 to 20.5) | 20.5 (20.5 to 20.5) |
| 1 Month after Dose 2 | 969.6 (905.7 to 1038.0) | 913.0 (843.4 to 988.3) |
GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 at 1 month after Dose 2 to the geometric mean titers of SARS-CoV-2 at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.
| Fold rise | BNT162b2 30 mcg: US Lot 1 | BNT162b2 20 mcg: US Lot 1 |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study | 47.3 (44.2 to 50.6) | 44.5 (41.1 to 48.2) |
Collected over AEs and SAEs-For primary study: From Dose 1 to 1 Month after Dose 2 (up to a maximum of 2 months); For booster study: From Dose 3 to 1 Month after Dose 3 (up to a maximum of 35 days); Local reactions/systemic events: Within 7 days after each dose. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BNT162b2 30 mcg: US Lot 1 | 0/351 (0%) | 0/351 (0%) | 341/351 (97.2%) |
| BNT162b2 30 mcg: US Lot 2 | 0/352 (0%) | 0/352 (0%) | 336/352 (95.5%) |
| BNT162b2 30 mcg: US Lot 3 | 0/346 (0%) | 1/346 (0.3%) | 335/347 (96.5%) |
| BNT162b2 30 mcg: EU Lot | 0/173 (0%) | 1/173 (0.6%) | 165/173 (95.4%) |
| BNT162b2 20 mcg: US Lot 1 | 0/351 (0%) | 0/351 (0%) | 342/351 (97.4%) |
| BNT162b2 30 mcg: Booster Dose | 0/31 (0%) | 0/31 (0%) | 30/31 (96.8%) |
| BNT162b2.B.1.351 30 mcg: Booster Dose | 0/31 (0%) | 0/31 (0%) | 31/31 (100%) |
| Event | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|---|---|---|---|---|
| MigrainosusNervous system disorders | 0/351 | 0/352 | 0/346 | 1/173 | 0/351 | 0/31 | 0/31 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/351 | 0/352 | 1/346 | 0/173 | 0/351 | 0/31 | 0/31 |
| Event | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | BNT162b2 30 mcg: Booster Dose | BNT162b2.B.1.351 30 mcg: Booster Dose |
|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 319/351 | 302/352 | 316/347 | 158/173 | 314/351 | 28/31 | 29/31 |
| FatigueGeneral disorders | 276/351 | 259/352 | 281/347 | 133/173 | 265/351 | 21/31 | 26/31 |
| HeadacheNervous system disorders | 234/351 | 229/352 | 223/347 | 119/173 | 224/351 | 13/31 | 18/31 |
| MyalgiaMusculoskeletal and connective tissue disorders | 136/351 | 153/352 | 150/347 | 76/173 | 142/351 | 13/31 | 6/31 |
| ChillsGeneral disorders | 115/351 | 120/352 | 129/347 | 56/173 | 92/351 | 8/31 | 6/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 82/351 | 96/352 | 83/347 | 42/173 | 78/351 | 4/31 | 4/31 |
| DiarrhoeaGastrointestinal disorders | 57/351 | 50/352 | 48/347 | 26/173 | 54/351 | 5/31 | 2/31 |
| Injection site erythemaGeneral disorders | 16/351 | 19/352 | 23/347 | 8/173 | 16/351 | 3/31 | 1/31 |
| PyrexiaGeneral disorders | 26/351 | 22/352 | 29/347 | 16/173 | 20/351 | 1/31 | 2/31 |
| Injection site swellingGeneral disorders | 21/351 | 31/352 | 25/347 | 8/173 | 22/351 | 2/31 | 2/31 |
Safety Population comprising of all randomized participants who received at least 1 dose of the study intervention were included.
| Age, Continuous(Years) | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | Total |
|---|---|---|---|---|---|---|
| Mean | 28.0 ± 11.66 | 27.8 ± 11.76 | 27.5 ± 11.54 | 27.7 ± 11.40 | 27.5 ± 11.71 | 27.7 ± 11.63 |
| Sex: Female, Male(Participants) | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | Total |
|---|---|---|---|---|---|---|
| Female | 177 | 176 | 159 | 83 | 163 | 758 |
| Male | 174 | 176 | 187 | 90 | 188 | 815 |
| Ethnicity (NIH/OMB)(Participants) | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 44 | 32 | 55 | 22 | 42 | 195 |
| Not Hispanic or Latino | 306 | 319 | 291 | 151 | 309 | 1376 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | BNT162b2 30 mcg: US Lot 1 | BNT162b2 30 mcg: US Lot 2 | BNT162b2 30 mcg: US Lot 3 | BNT162b2 30 mcg: EU Lot | BNT162b2 20 mcg: US Lot 1 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 3 | 5 |
| Asian | 36 | 48 | 40 | 24 | 44 | 192 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 0 | 2 | 5 |
| Black or African American | 21 | 16 | 15 | 2 | 14 | 68 |
| White | 286 | 280 | 283 | 142 | 283 | 1274 |
| More than one race | 6 | 5 | 5 | 4 | 5 | 25 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Jul 2021, 5 months.
Results were first posted in Dec 2022, 1 year 5 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine